- Home
- BTAI vs HOTH Comparison
BTAI vs HOTH Comparison
Compare BTAI & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- HOTH
- Stock Information
- Founded
- BTAI 2017
- HOTH 2017
- Country
- BTAI United States
- HOTH United States
- Employees
- BTAI N/A
- HOTH N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- BTAI Health Care
- HOTH Health Care
- Exchange
- BTAI Nasdaq
- HOTH Nasdaq
- Market Cap
- BTAI 8.4M
- HOTH 8.3M
- IPO Year
- BTAI 2018
- HOTH 2019
- Fundamental
- Price
- BTAI $1.84
- HOTH $1.30
- Analyst Decision
- BTAI Buy
- HOTH Strong Buy
- Analyst Count
- BTAI 5
- HOTH 3
- Target Price
- BTAI $42.60
- HOTH $4.00
- AVG Volume (30 Days)
- BTAI 436.1K
- HOTH 2.4M
- Earning Date
- BTAI 08-05-2025
- HOTH 05-12-2025
- Dividend Yield
- BTAI N/A
- HOTH N/A
- EPS Growth
- BTAI N/A
- HOTH N/A
- EPS
- BTAI N/A
- HOTH N/A
- Revenue
- BTAI $1,852,000.00
- HOTH N/A
- Revenue This Year
- BTAI $5.03
- HOTH N/A
- Revenue Next Year
- BTAI $291.01
- HOTH N/A
- P/E Ratio
- BTAI N/A
- HOTH N/A
- Revenue Growth
- BTAI 5.47
- HOTH N/A
- 52 Week Low
- BTAI $1.17
- HOTH $0.58
- 52 Week High
- BTAI $25.92
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- BTAI 64.53
- HOTH 64.78
- Support Level
- BTAI $1.17
- HOTH $0.88
- Resistance Level
- BTAI $1.48
- HOTH $1.78
- Average True Range (ATR)
- BTAI 0.13
- HOTH 0.16
- MACD
- BTAI 0.06
- HOTH 0.05
- Stochastic Oscillator
- BTAI 100.00
- HOTH 50.72
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.